Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


"Multimodular biomarker analysis workflow for diagnosis, prognosis and monitoring of drug treatment response in bladder cancer"

Funder: European Commission

Funding period
EUR 3.5 M
USD 4.3 M
Funding amount
"With the advent of Omics technologies capable of profiling substantial fractions of molecular entities from the genome down to the metabolome level a significant boost in understanding disease pathophysiology, consequently providing tailored diagnostics and therapy, was expected. With impressive results for selected diseases, cancer still sees significant shortcomings. One reason for this clinical situation is certainly the apparent heterogeneity of cancers, manifesting in clinical presentation and outcome, but also on the personalized molecular level.
Within DIPROMON we selected bladder cancer as a prototypical example for the need of personalization efforts in therapy, and we plan of using this clinically highly challenging disease phenotype for establishing a general workflow for enabling personalization strategies towards rational decision on tailoring therapeutic interventions for defined patient groups. DIPROMON on its basis follows a computational Systems Biology approach for delineating statistical rules for patient segmentation, resting on patient-specific biomarker profiles interpreted in tight integration with patient-specific clinical data. DIPROMON will establish a workflow including quality control aspects for i) selecting biomarker panels for given clinical phenotypes, ii) providing modular instrumentation for measuring the profiles in a clinical setting, and iii) deriving statistics-driven rules for patient segmentation regarding optimal therapy. DIPROMON will finally validate the concept in bladder cancer."
Similar projects All >
Sorted by: Start Date
Project list item
Molecular profiling of Bladder Cancer to support personalized medicine

European Commission to Maria Frantzi

USD 183,796
2017 - 2019



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC


  • RCDC


  • RCDC

    Patient Safety

  • RCDC

    Urologic Diseases




    4.1 Discovery and preclinical testing of markers and technologies

  • Broad Research Areas

    Clinical Medicine and Science